{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-028451","form_type":"8-K","ticker":"IVF","cik":"0001417926","company_name":"INVO Fertility, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.862757+00:00","generated_at":"2026-06-11T10:37:33.751938+00:00","sec_items":["2.02","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"INVO Bioscience Q2 revenue up 116% to $316K; closes WFI acquisition for $10M","bullets":["Revenue $315,902 (+116% YoY); clinic revenue $254,364 (+126%); all clinics $712,433 (+145%).","Acquired Wisconsin Fertility Institute for $10M (3-yr payment); WFI 2022 rev $5.4M, net income $1.7M.","Adjusted EBITDA -$1.6M (vs. -$2.2M); cash $0.1M at 6/30; $4.5M raised in public offering post-Q.","Expects clinic ops cash flow positive in Q3 2023, overall operating cash flow positive in 2024.","Received FDA 510(k) clearance for expanded use of INVOcell device."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-028451","json":"https://secwatch.observer/filing/0001493152-23-028451.json","markdown":"https://secwatch.observer/filing/0001493152-23-028451.md","text":"https://secwatch.observer/filing/0001493152-23-028451.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223028451/0001493152-23-028451-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223028451/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T10:37:33.751938+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"04d6a9159c19540a15fc044c0f8f9d1be99b11cb","claim":"INVO Fertility, Inc. reported the second quarter ended June 30, 2023 results: revenue $315,902.","evidence_excerpt":"for the second quarter ended June 30, 2023 and provided a business update. Q2 2023 Financial Highlights (all metrics compared to Q2 2022 unless otherwise noted) ● Revenue was $315,902, an increase of 116% compared to $146,135. ● Clinic revenue increased 126% to $254,364, compared to $112,358. All reported clinic revenue is derived from the Company’s INVO","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223028451/0001493152-23-028451-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$315,902"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}